A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Study Details
Study Description
Brief Summary
This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1
|
Drug: ketorolac
Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.
Placebo
|
Placebo Comparator: 2
|
Drug: ketorolac
Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.
Placebo
|
Outcome Measures
Primary Outcome Measures
- Resolution of Post Operative Inflammation [Day 14]
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells)
Secondary Outcome Measures
- Ocular Pain [Day 1]
Measured on a scale of 0-4 (0 = none, 4 = intolerable)
- Mean Pupil Area [Day 0]
Pupil area post-irrigation and aspiration
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients undergoing cataract surgery
Exclusion Criteria:
- Uncontrolled ocular disease in cataract surgery eye
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Artesia | California | United States |
Sponsors and Collaborators
- Allergan
Investigators
- Study Director: Medical Director, Allergan
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 191578-005
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Ketorolac Solution | Vehicle Solution |
---|---|---|
Arm/Group Description | ||
Period Title: Overall Study | ||
STARTED | 164 | 84 |
COMPLETED | 144 | 57 |
NOT COMPLETED | 20 | 27 |
Baseline Characteristics
Arm/Group Title | Ketorolac Solution | Vehicle Solution | Total |
---|---|---|---|
Arm/Group Description | Total of all reporting groups | ||
Overall Participants | 164 | 84 | 248 |
Age, Customized (participants) [Number] | |||
<45 years |
3
1.8%
|
2
2.4%
|
5
2%
|
Between 45 and 65 years |
53
32.3%
|
33
39.3%
|
86
34.7%
|
>65 years |
108
65.9%
|
49
58.3%
|
157
63.3%
|
Sex: Female, Male (Count of Participants) | |||
Female |
92
56.1%
|
49
58.3%
|
141
56.9%
|
Male |
72
43.9%
|
35
41.7%
|
107
43.1%
|
Outcome Measures
Title | Resolution of Post Operative Inflammation |
---|---|
Description | Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) |
Time Frame | Day 14 |
Outcome Measure Data
Analysis Population Description |
---|
Modified Intent-to-Treat Population |
Arm/Group Title | Ketorolac Solution | Vehicle Solution |
---|---|---|
Arm/Group Description | ||
Measure Participants | 149 | 78 |
Number [% of participants with a score of 0] |
46.3
28.2%
|
25.6
30.5%
|
Title | Ocular Pain |
---|---|
Description | Measured on a scale of 0-4 (0 = none, 4 = intolerable) |
Time Frame | Day 1 |
Outcome Measure Data
Analysis Population Description |
---|
Modified Intent-to-Treat Population |
Arm/Group Title | Ketorolac Solution | Vehicle Solution |
---|---|---|
Arm/Group Description | ||
Measure Participants | 152 | 78 |
Number [% of participants with a score of 0] |
75.0
45.7%
|
41.0
48.8%
|
Title | Mean Pupil Area |
---|---|
Description | Pupil area post-irrigation and aspiration |
Time Frame | Day 0 |
Outcome Measure Data
Analysis Population Description |
---|
Modified Intent-to-Treat Population |
Arm/Group Title | Ketorolac Solution | Vehicle Solution |
---|---|---|
Arm/Group Description | ||
Measure Participants | 154 | 78 |
Mean (Standard Deviation) [millimeters squared (mm²)] |
41.8
(12.6)
|
41.1
(14.0)
|
Title | Visual Acuity |
---|---|
Description | Patients with ≥ 3 line improvement in visual acuity |
Time Frame | Change from baseline at Day 14 |
Outcome Measure Data
Analysis Population Description |
---|
Modified Intent-to-Treat Population |
Arm/Group Title | Ketorolac Solution | Vehicle Solution |
---|---|---|
Arm/Group Description | ||
Measure Participants | 153 | 78 |
Number [Percentage of patients with ≥ 3 lines] |
59.5
|
46.2
|
Adverse Events
Time Frame | ||||
---|---|---|---|---|
Adverse Event Reporting Description | ||||
Arm/Group Title | Ketorolac Solution | Vehicle Solution | ||
Arm/Group Description | ||||
All Cause Mortality |
||||
Ketorolac Solution | Vehicle Solution | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
Ketorolac Solution | Vehicle Solution | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 2/ (NaN) | 1/ (NaN) | ||
Cardiac disorders | ||||
Angina Unstable | 1/157 (0.6%) | 0/81 (0%) | ||
Cardiac Arrest | 1/157 (0.6%) | 0/81 (0%) | ||
Coronary Artery Occlusion | 1/157 (0.6%) | 0/81 (0%) | ||
Coronary Artery Disease | 0/157 (0%) | 1/81 (1.2%) | ||
Other (Not Including Serious) Adverse Events |
||||
Ketorolac Solution | Vehicle Solution | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 46/ (NaN) | 52/ (NaN) | ||
Eye disorders | ||||
Foreign body sensation in eyes | 8/157 (5.1%) | 5/81 (6.2%) | ||
Iritis | 8/157 (5.1%) | 5/81 (6.2%) | ||
Eye Pain | 7/157 (4.5%) | 15/81 (18.5%) | ||
Conjunctival Hyperemia | 3/157 (1.9%) | 12/81 (14.8%) | ||
Photophobia | 2/157 (1.3%) | 8/81 (9.9%) | ||
Intraocular Pressure Increased | 9/157 (5.7%) | 2/81 (2.5%) | ||
Nervous system disorders | ||||
Headache | 9/157 (5.7%) | 5/81 (6.2%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Name/Title | Therapeutic Area Head |
---|---|
Organization | Allergan, Inc. |
Phone | (714)246-4500 |
clinicaltrials@allergan.com |
- 191578-005